Breast cancer specialists review key efficacy and safety data from the DESTINY-Breast04 trial investigating trastuzumab deruxtecan in patients with HR+/HER2-low metastatic breast cancer.
Video content above is prompted by the following questions:
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen